Archive

HIGHLIGHTS

 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here

2018


argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
Favorable safety and tolerability consistent with efgartigimod clinical trials to date   Clinically meaningful platelet count improvements showed clear separation from placebo at increasing response thresh [...]
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat [...]
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets
Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales   Heidelberg, Germany, August 27, 2018 [...]
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Merus Announces Formation of a Scientific Advisory Board
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies -    UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here

$smarty.now|date_format:"%Y"


argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
Favorable safety and tolerability consistent with efgartigimod clinical trials to date   Clinically meaningful platelet count improvements showed clear separation from placebo at increasing response thresh [...]
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat [...]
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets
Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales   Heidelberg, Germany, August 27, 2018 [...]
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Merus Announces Formation of a Scientific Advisory Board
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies -    UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview